JP2005502882A5 - - Google Patents

Claims (23)

Infectious spongiform encephalopathy (TSE) or a method of diagnosing that possibility in a subject suspected of suffering from the TSE is:
Subjecting a sample of body fluid removed from the subject to mass spectrometry, thereby determining a test amount of the polypeptide in the sample;
Determining whether the test quantity corresponds to a diagnosis of the TSE;
The polypeptide is contained differently in the body fluids of TSE infected and non-infected subjects and is about 4780, about 6700, about 8600, about 13375, about 3970, about 3990, about 4294, about 4478, about 10075. , About 11730, about 14043, about 17839, about 7700, about 3295, about 4315, about 4436, about 6200, about 8936, about 9107, about 9145, about 9185, about 9454, about 13550, about 7574, about 7930, about It has a molecular weight of 7975, about 8020, or about 10220 Da.   2. The polypeptide of claim 1, wherein the polypeptide is present in the body fluid of a TSE infected subject and not in the body fluid of a non-TSE infected subject, thereby indicating that the presence of the polypeptide in a body fluid sample is TSE. Method.   2. The polypeptide is not present in the body fluid of a TSE-infected subject but is present in the body fluid of a non-TSE-infected subject, thereby indicating that the absence of the polypeptide in the body fluid sample is TSE. the method of.   The method according to claim 1, wherein the mass spectrometry is laser desorption / ionization mass spectrometry.   5. The sample of claim 1, wherein the sample is absorbed with a probe having immobilized metal affinity capture (IMAC), a hydrophobic, strong anionic, or weakly cationic exchange surface that binds to the polypeptide. The method according to item.   6. The method of any one of claims 1-5, wherein the polypeptide is determined by surface amplified laser desorption / ionization (SELDI) and time-of-flight mass spectrometry (TOF-MS).   The method according to any one of claims 1 to 6, wherein the body fluid is cerebrospinal fluid, plasma, serum, blood, or tears.   8. The method of any one of claims 1 to 7, wherein a plurality of the polypeptides are determined within the sample.   The method according to any one of claims 1 to 8, wherein the TSE is Creutzfeldt-Jakob disease (CJD).   One or more respective polypeptides having a molecular weight of about 4780, about 6700, about 8600, or about 13375 are determined, indicating that the presence of one or more of such polypeptides is CJD The method of claim 9.   One or more polypeptides each having a molecular weight of about 3970, about 3990, about 4294, about 4478, about 10075, about 11730, about 14043, or about 17839 are determined, and one or more of such polypeptides 11. A method according to claim 9 or 10, wherein a greater absence indicates CJD.   12. A method according to any one of claims 9 to 11 wherein a polypeptide having a molecular weight of about 7700 is determined and the presence of such a polypeptide is CJD.   A polypeptide having a molecular weight of about 3295, about 4315, about 4436, about 6200, about 8936, about 9107, about 9145, about 9185, about 9454, or about 13550 Da is determined, and one or more of such polypeptides 13. A method according to any one of claims 9 to 12, wherein the absence or reduction amount indicates CJD.   The polypeptide of claim 9 to 13, wherein a polypeptide having a molecular weight of about 7574, about 7930, about 7975, or about 8020 Da is determined and indicates that the presence or increase of one or more of such polypeptides is CJD The method according to any one of the above.   9. The method according to any one of claims 1 to 8, wherein the TSE is bovine spongiform encephalopathy (BSE).   16. The method of claim 15, wherein the polypeptide has a molecular weight of about 10220, wherein the presence of the polypeptide is BSE.   9. A method according to any one of claims 1 to 8, wherein the TSE is scrapie. Use of a polypeptide that is differentially contained in the body fluids of a TSE-infected subject and a non-infected subject for diagnostic, predictive, therapeutic applications,
The polypeptide comprises about 4780, about 6700, about 8600, about 13375, about 3970, about 3990, about 4294, about 4478, about 10075, about 11730, about 14043, about 17839, about 7700, about 3295, about 4315, Having a molecular weight of about 4436, about 6200, about 8936, about 9107, about 9145, about 9185, about 9454, about 13550, about 7574, about 7930, about 7975, about 8020, or about 10220 Da, determined by mass spectrometry be able to. The use of materials for diagnostic, predictive, therapeutic applications,
The material recognizes a polypeptide contained differently in the body fluid of a TSE-infected subject and a non-infected subject, binds to the polypeptide, or has an affinity for the polypeptide,
The pre-polypeptide is about 4780, about 6700, about 8600, about 13375, about 3970, about 3990, about 4294, about 4478, about 10075, about 11730, about 14043, about 17839, about 7700, about 3295, about 4315, Having a molecular weight of about 4436, about 6200, about 8936, about 9107, about 9145, about 9185, about 9454, about 13550, about 7574, about 7930, about 7975, about 8020, or about 10220 Da, determined by mass spectrometry be able to.   The use according to claim 19, wherein the material is an antibody or an antibody chip. A kit for use in diagnosis of TSE comprising a probe for receiving a sample of body fluid and placing it in mass spectrometry;
Thereby determining the test amount of polypeptide in the sample,
The polypeptide is contained differently in body fluids between TSE-infected subjects and non-TSE-infected subjects,
The polypeptide is about 4780, about 6700, about 8600, about 13375, about 3970, about 3990, about 4294, about 4478, about 10075, about 11730, about 14043, about 17839, about 7700, about 3295, about 4315, It has a molecular weight of about 4436, about 6200, about 8936, about 9107, about 9145, about 9185, about 9454, about 13550, about 7574, about 7930, about 7975, about 8020, or about 10220 Da.   The kit of claim 21, wherein the probe comprises an adsorbent for absorption of the polypeptide.   23. The kit of claim 22, further comprising a wash solution for removing unbound or weakly bound material from the probe.